Finerenone NEW
| Price | $31 | $74 | $116 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-06 |
Product Details
| Product Name: Finerenone | CAS No.: 1050477-31-0 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2026/05/06 |
Product Introduction
Bioactivity
| Name | Finerenone |
| Description | Finerenone (BAY-948862) is a nonsteroidal antagonist of the mineralocorticoid receptor (MR) (IC50=18 nM) with selective and oral activity. Finerenone is used in the treatment of patients with chronic kidney disease with type 2 diabetes. |
| In vitro | METHODS: Human smooth muscle cells SMC and human endothelial cells EC were treated with aldosterone (1-50 nM) and Finerenone (1-10 nM) for 24 h. Cell proliferation was detected by BrdU incorporation assay. RESULTS: After stimulation with aldosterone, the proliferation rate of SMC increased significantly. Although treatment with 1 nM concentration of Finerenone showed a clear tendency to decrease the SMC proliferation rate, 10 nM Finerenone adequately and significantly blocked aldosterone-induced SMC proliferation. However, aldosterone did not affect EC proliferation in vitro, nor did Finerenone. [1] METHODS: HK-GFP-hMR cells were treated with aldosterone (10 nM) and Finerenone (1 μM) for 3 h. The gene expression levels were measured by RT-qPCR. RESULTS: Finerenone was effective in antagonizing some aldosterone-induced genes. [2] |
| In vivo | METHODS: To investigate the effects on vascular remodeling after acute vascular injury, Finerenone (1-10 mg/kg) was administered orally once daily for 21 days to wire-induced femoral artery dilated C57BL/6 mice. RESULTS: Finerenone treatment inhibited intimal and intermediate cell proliferation after wire-induced injury in mouse femoral arteries at 10 days post-injury and attenuated the formation of neoplastic intimal injury at 21 days post-injury. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (158.55 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 6 mg/mL (15.86 mM), Solution. H2O : Insoluble |
| Keywords | type | systolic | pressure | oral | nonsteroidal | Mineralocorticoid Receptor | kidney | Inhibitor | inhibit | GlucocorticoidReceptor | Glucocorticoid Receptor | Finerenone | disease | diabetes | chronic | cardiorenal | blood |
| Inhibitors Related | Nimodipine | Betamethasone | Mifepristone | Prednisolone acetate | Beclometasone | Cortisone | Dexamethasone acetate | Dexamethasone | Betamethasone dipropionate | Dexamethasone Phosphate disodium | Prednisone acetate | Megestrol acetate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP2Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-05-20 | ||
| $85.00 |
VIP3Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2026-05-05 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
|
VIP4Y
|
shandong perfect biotechnology co.ltd
|
2026-03-27 | ||
|
VIP3Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2026-01-04 | ||
|
Wuhan Biocar Pharmacy CO.,Ltd.
|
2025-12-25 | |||
|
Guangzhou Tosun Pharmaceutical Ltd
|
2025-12-19 | |||
|
VIP7Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2025-12-15 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-12-11 | ||
|
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
|
2025-05-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY